Syncor wins clearance for palladium seeds

Article

Radiopharmaceutical firm Syncor International has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer. In December, the FDA cleared Woodland Hills,

Radiopharmaceutical firm Syncor International has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer. In December, the FDA cleared Woodland Hills, CA-based Syncor’s iodine-125 seeds, also for prostate cancer (SCAN 2/2/00). The company plans to market the two products under the trade name PharmaSeed.

In other Syncor news, the firm announced the resignation of Brad Nutter, executive vice president and COO. Nutter left Syncor on Feb. 11 for the position of president of Gambro Healthcare. While Syncor seeks a permanent replacement for Nutter, its pharmacy services executive team will report to president and CEO Robert Funari.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.